Tissue-specific actions of FXR in metabolism and cancer

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1851, Issue 1, 2015, Pages 30-39

  Gadaleta, Raffaella Maria ^a   Cariello, Marica ^b   Sabbà, Carlo ^c   Moschetta, Antonio ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Bile acid homeostasis; Farnesoid X receptor; Gut liver axis; Hepatic and colorectal carcinogenesis; Selective FXR ligands

Indexed keywords

BILE ACID; FARNESOID X RECEPTOR; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GLUCOSE;

COLON CANCER; COLON CARCINOGENESIS; ENTEROHEPATIC CIRCULATION; GLUCOSE METABOLISM; HEPATOBILIARY SYSTEM; HUMAN; INTESTINE; KNOCKOUT MOUSE; LIPID METABOLISM; LIPIDOMICS; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METABOLIC REGULATION; MOUSE MODEL; NONHUMAN; PROTEIN FUNCTION; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE SPECIFICITY; TRANSGENIC MOUSE; ANIMAL; HOMEOSTASIS; METABOLISM; NEOPLASM;

ANIMALS; GLUCOSE; HOMEOSTASIS; HUMANS; INTESTINES; LIVER; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84911903234     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2014.08.005     Document Type: Review

References (153)

1. D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, and R.M. Evans The nuclear receptor superfamily: the second decade Cell 83 1995 835 839
2. W. Seol, H.S. Choi, and D.D. Moore Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors Mol. Endocrinol. 9 1995 72 85
3. B.M. Forman, E. Goode, J. Chen, A.E. Oro, D.J. Bradley, T. Perlmann, D.J. Noonan, L.T. Burka, T. McMorris, W.W. Lamph, R.M. Evans, and C. Weinberger Identification of a nuclear receptor that is activated by farnesol metabolites Cell 81 1995 687 693
4. M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, A. Luk, M.V. Hull, K.D. Lustig, D.J. Mangelsdorf, and B. Shan Identification of a nuclear receptor for bile acids Science 284 1999 1362 1365
5. D.J. Parks, S.G. Blanchard, R.K. Bledsoe, G. Chandra, T.G. Consler, S.A. Kliewer, J.B. Stimmel, T.M. Willson, A.M. Zavacki, D.D. Moore, and J.M. Lehmann Bile acids: natural ligands for an orphan nuclear receptor Science 284 1999 1365 1368
6. H. Wang, J. Chen, K. Hollister, L.C. Sowers, and B.M. Forman Endogenous bile acids are ligands for the nuclear receptor FXR/BAR Mol. Cell 3 1999 543 553
7. M. Ananthanarayanan, S. Li, N. Balasubramaniyan, F.J. Suchy, and M.J. Walsh Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1 J. Biol. Chem. 279 2004 54348 54357
8. T.T. Lu, J.J. Repa, and D.J. Mangelsdorf Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism J. Biol. Chem. 276 2001 37735 37738
9. Y. Zhang, H.R. Kast-Woelbern, and P.A. Edwards Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation J. Biol. Chem. 278 2003 104 110
10. K.E. Swales, M. Korbonits, R. Carpenter, D.T. Walsh, T.D. Warner, and D. Bishop-Bailey The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression Cancer Res. 66 2006 10120 10126
11. T. Fujino, M. Une, T. Imanaka, K. Inoue, and T. Nishimaki-Mogami Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation J. Lipid Res. 45 2004 132 138
12. S. Fiorucci, A. Mencarelli, G. Palladino, and S. Cipriani Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders Trends Pharmacol. Sci. 30 2009 570 580
13. P.R. Maloney, D.J. Parks, C.D. Haffner, A.M. Fivush, G. Chandra, K.D. Plunket, K.L. Creech, L.B. Moore, J.G. Wilson, M.C. Lewis, S.A. Jones, and T.M. Willson Identification of a chemical tool for the orphan nuclear receptor FXR J. Med. Chem. 43 2000 2971 2974
14. C. Thomas, R. Pellicciari, M. Pruzanski, J. Auwerx, and K. Schoonjans Targeting bile-acid signalling for metabolic diseases Nat. Rev. Drug Discov. 7 2008 678 693
15. S. Mudaliar, R.R. Henry, A.J. Sanyal, L. Morrow, H.U. Marschall, M. Kipnes, L. Adorini, C.I. Sciacca, P. Clopton, E. Castelloe, P. Dillon, M. Pruzanski, and D. Shapiro Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 145 2013 574 582
16. B. Goodwin, S.A. Jones, R.R. Price, M.A. Watson, D.D. McKee, L.B. Moore, C. Galardi, J.G. Wilson, M.C. Lewis, M.E. Roth, P.R. Maloney, T.M. Willson, and S.A. Kliewer A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis Mol. Cell 6 2000 517 526
17. Y.K. Lee, and D.D. Moore Liver receptor homolog-1, an emerging metabolic modulator Front. Biosci. 13 2008 5950 5958
18. T.T. Lu, M. Makishima, J.J. Repa, K. Schoonjans, T.A. Kerr, J. Auwerx, and D.J. Mangelsdorf Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors Mol. Cell 6 2000 507 515
19. M. Zhang, and J.Y. Chiang Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression J. Biol. Chem. 276 2001 41690 41699
20. A. Moschetta, G.P. vanBerge-Henegouwen, P. Portincasa, G. Palasciano, and K.J. van Erpecum Cholesterol crystallization in model biles: effects of bile salt and phospholipid species composition J. Lipid Res. 42 2001 1273 1281
21. C.N. Falany, M.R. Johnson, S. Barnes, and R.B. Diasio Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase J. Biol. Chem. 269 1994 19375 19379
22. K. Solaas, A. Ulvestad, O. Soreide, and B.F. Kase Subcellular organization of bile acid amidation in human liver: a key issue in regulating the biosynthesis of bile salts J. Lipid Res. 41 2000 1154 1162
23. P.C. Pircher, J.L. Kitto, M.L. Petrowski, R.K. Tangirala, E.D. Bischoff, I.G. Schulman, and S.K. Westin Farnesoid X receptor regulates bile acid-amino acid conjugation J. Biol. Chem. 278 2003 27703 27711
24. A.C. Calkin, and P. Tontonoz Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR Nat. Rev. Mol. Cell Biol. 13 2012 213 224
25. T. Gerloff, B. Stieger, B. Hagenbuch, J. Madon, L. Landmann, J. Roth, A.F. Hofmann, and P.J. Meier The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver J. Biol. Chem. 273 1998 10046 10050
26. R. Wang, M. Salem, I.M. Yousef, B. Tuchweber, P. Lam, S.J. Childs, C.D. Helgason, C. Ackerley, M.J. Phillips, and V. Ling Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis Proc. Natl. Acad. Sci. U. S. A. 98 2001 2011 2016
27. L. Huang, A. Zhao, J.L. Lew, T. Zhang, Y. Hrywna, J.R. Thompson, P.N. de, I. Royo, R.A. Blevins, F. Pelaez, S.D. Wright, and J. Cui Farnesoid X receptor activates transcription of the phospholipid pump MDR3 J. Biol. Chem. 278 2003 51085 51090
28. J.J. Smit, A.H. Schinkel, R.P. Oude Elferink, A.K. Groen, E. Wagenaar, D.L. van, C.A. Mol, R. Ottenhoff, N.M. van der Lugt, and M.A. van Roon Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease Cell 75 1993 451 462
29. S.S. Strautnieks, L.N. Bull, A.S. Knisely, S.A. Kocoshis, N. Dahl, H. Arnell, E. Sokal, K. Dahan, S. Childs, V. Ling, M.S. Tanner, A.F. Kagalwalla, A. Nemeth, J. Pawlowska, A. Baker, G. Mieli-Vergani, N.B. Freimer, R.M. Gardiner, and R.J. Thompson A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis Nat. Genet. 20 1998 233 238
30. J.M. de Vree, E. Jacquemin, E. Sturm, D. Cresteil, P.J. Bosma, J. Aten, J.F. Deleuze, M. Desrochers, M. Burdelski, O. Bernard, R.P. Oude Elferink, and M. Hadchouel Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis Proc. Natl. Acad. Sci. U. S. A. 95 1998 282 287
31. N. Chignard, and R. Poupon Targeting farnesoid x receptor in hepatic and biliary inflammatory diseases Gastroenterology 137 2009 734 735
32. N. Chignard, M. Mergey, V. Barbu, L. Finzi, E. Tiret, A. Paul, and C. Housset VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium Hepatology 42 2005 549 557
33. E. D'Aldebert, M.J. Biyeyeme Bi Mve, M. Mergey, D. Wendum, D. Firrincieli, A. Coilly, L. Fouassier, C. Corpechot, R. Poupon, C. Housset, and N. Chignard Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium Gastroenterology 136 2009 1435 1443
34. M.H. Wong, P. Oelkers, and P.A. Dawson Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity J. Biol. Chem. 270 1995 27228 27234
35. T. Inagaki, M. Choi, A. Moschetta, L. Peng, C.L. Cummins, J.G. McDonald, G. Luo, S.A. Jones, B. Goodwin, J.A. Richardson, R.D. Gerard, J.J. Repa, D.J. Mangelsdorf, and S.A. Kliewer Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis Cell Metab. 2 2005 217 225
36. I. Kim, S.H. Ahn, T. Inagaki, M. Choi, S. Ito, G.L. Guo, S.A. Kliewer, and F.J. Gonzalez Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine J. Lipid Res. 48 2007 2664 2672
37. Y.Z. Gong, E.T. Everett, D.A. Schwartz, J.S. Norris, and F.A. Wilson Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol Proc. Natl. Acad. Sci. U. S. A. 91 1994 4741 4745
38. G.P. Tochtrop, G.T. DeKoster, D.F. Covey, and D.P. Cistola A single hydroxyl group governs ligand site selectivity in human ileal bile acid binding protein J. Am. Chem. Soc. 126 2004 11024 11029
39. O. Toke, J.D. Monsey, G.T. DeKoster, G.P. Tochtrop, C. Tang, and D.P. Cistola Determinants of cooperativity and site selectivity in human ileal bile acid binding protein Biochemistry 45 2006 727 737
40. P.A. Dawson, M. Hubbert, J. Haywood, A.L. Craddock, N. Zerangue, W.V. Christian, and N. Ballatori The heteromeric organic solute transporter alpha-beta, OSTalpha-OSTbeta, is an ileal basolateral bile acid transporter J. Biol. Chem. 280 2005 6960 6968
41. J. Grober, I. Zaghini, H. Fujii, S.A. Jones, S.A. Kliewer, T.M. Willson, T. Ono, and P. Besnard Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer J. Biol. Chem. 274 1999 29749 29754
42. T. Kok, C.V. Hulzebos, H. Wolters, R. Havinga, L.B. Agellon, F. Stellaard, B. Shan, M. Schwarz, and F. Kuipers Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein J. Biol. Chem. 278 2003 41930 41937
43. J.F. Landrier, J.J. Eloranta, S.R. Vavricka, and G.A. Kullak-Ublick The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes Am. J. Physiol. Gastrointest. Liver Physiol. 290 2006 G476 G485
44. A. Rao, J. Haywood, A.L. Craddock, M.G. Belinsky, G.D. Kruh, and P.A. Dawson The organic solute transporter alpha-beta, OSTalpha-OSTbeta, is essential for intestinal bile acid transport and homeostasis Proc. Natl. Acad. Sci. U. S. A. 105 2008 3891 3896
45. C. Gnerre, S. Blattler, M.R. Kaufmann, R. Looser, and U.A. Meyer Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene Pharmacogenetics 14 2004 635 645
46. C.S. Song, I. Echchgadda, B.S. Baek, S.C. Ahn, T. Oh, A.K. Roy, and B. Chatterjee Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor J. Biol. Chem. 276 2001 42549 42556
47. M.W. Love, and P.A. Dawson New insights into bile acid transport Curr. Opin. Lipidol. 9 1998 225 229
48. C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, and F.J. Gonzalez Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 2000 731 744
49. S.G. Lo, M. Petruzzelli, and A. Moschetta A translational view on the biliary lipid secretory network Biochim. Biophys. Acta 1781 2008 79 96
50. A. Moschetta, A.L. Bookout, and D.J. Mangelsdorf Prevention of cholesterol gallstone disease by FXR agonists in a mouse model Nat. Med. 10 2004 1352 1358
51. Y. Zhang, F.Y. Lee, G. Barrera, H. Lee, C. Vales, F.J. Gonzalez, T.M. Willson, and P.A. Edwards Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice Proc. Natl. Acad. Sci. U. S. A. 103 2006 1006 1011
52. K. Ma, P.K. Saha, L. Chan, and D.D. Moore Farnesoid X receptor is essential for normal glucose homeostasis J. Clin. Invest. 116 2006 1102 1109
53. G. Lambert, M.J. Amar, G. Guo, H.B. Brewer Jr., F.J. Gonzalez, and C.J. Sinal The farnesoid X-receptor is an essential regulator of cholesterol homeostasis J. Biol. Chem. 278 2003 2563 2570
54. D. Duran-Sandoval, B. Cariou, F. Percevault, N. Hennuyer, A. Grefhorst, T.H. van Dijk, F.J. Gonzalez, J.C. Fruchart, F. Kuipers, and B. Staels The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition J. Biol. Chem. 280 2005 29971 29979
55. Y.D. Wang, W.D. Chen, M. Wang, D. Yu, B.M. Forman, and W. Huang Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response Hepatology 48 2008 1632 1643
56. R.M. Gadaleta, K.J. van Erpecum, B. Oldenburg, E.C. Willemsen, W. Renooij, S. Murzilli, L.W. Klomp, P.D. Siersema, M.E. Schipper, S. Danese, G. Penna, G. Laverny, L. Adorini, A. Moschetta, and S.W. van Mil Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Gut 60 2011 463 472
57. R.M. Gadaleta, B. Oldenburg, E.C. Willemsen, M. Spit, S. Murzilli, L. Salvatore, L.W. Klomp, P.D. Siersema, K.J. van Erpecum, and S.W. van Mil Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-kappaB signaling in the intestine Biochim. Biophys. Acta 1812 2011 851 858
58. R.M. Nijmeijer, R.M. Gadaleta, S.W. van Mil, A.A. van Bodegraven, J.B. Crusius, G. Dijkstra, D.W. Hommes, D.J. de Jong, P.C. Stokkers, H.W. Verspaget, R.K. Weersma, C.J. van der Woude, J.M. Stapelbroek, M.E. Schipper, C. Wijmenga, K.J. van Erpecum, and B. Oldenburg Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease PLoS One 6 2011 e23745
59. F.D. van Schaik, R.M. Gadaleta, F.G. Schaap, S.W. van Mil, P.D. Siersema, B. Oldenburg, and K.J. van Erpecum Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis PLoS One 7 2012 e49706
60. P. Vavassori, A. Mencarelli, B. Renga, E. Distrutti, and S. Fiorucci The bile acid receptor FXR is a modulator of intestinal innate immunity J. Immunol. 183 2009 6251 6261
61. F. Yang, X. Huang, T. Yi, Y. Yen, D.D. Moore, and W. Huang Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor Cancer Res. 67 2007 863 867
62. A. Abrahamsson, U. Gustafsson, E. Ellis, L.M. Nilsson, S. Sahlin, I. Bjorkhem, and C. Einarsson Feedback regulation of bile acid synthesis in human liver: importance of HNF-4alpha for regulation of CYP7A1 Biochem. Biophys. Res. Commun. 330 2005 395 399
63. T. Lundasen, C. Galman, B. Angelin, and M. Rudling Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man J. Intern. Med. 260 2006 530 536
64. W.D. Chen, Y.D. Wang, Z. Meng, L. Zhang, and W. Huang Nuclear bile acid receptor FXR in the hepatic regeneration Biochim. Biophys. Acta 1812 2011 888 892
65. W. Huang, K. Ma, J. Zhang, M. Qatanani, J. Cuvillier, J. Liu, B. Dong, X. Huang, and D.D. Moore Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration Science 312 2006 233 236
66. L. Zhang, X. Huang, Z. Meng, B. Dong, S. Shiah, D.D. Moore, and W. Huang Significance and mechanism of CYP7a1 gene regulation during the acute phase of liver regeneration Mol. Endocrinol. 23 2009 137 145
67. Z. Meng, Y. Wang, L. Wang, W. Jin, N. Liu, H. Pan, L. Liu, L. Wagman, B.M. Forman, and W. Huang FXR regulates liver repair after CCl4-induced toxic injury Mol. Endocrinol. 24 2010 886 897
68. W.D. Chen, Y.D. Wang, L. Zhang, S. Shiah, M. Wang, F. Yang, D. Yu, B.M. Forman, and W. Huang Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription Hepatology 51 2010 953 962
69. L. Zhang, Y.D. Wang, W.D. Chen, X. Wang, G. Lou, N. Liu, M. Lin, B.M. Forman, and W. Huang Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice Hepatology 56 2012 2336 2343
70. S.W. van Mil, A. Milona, P.H. Dixon, R. Mullenbach, V.L. Geenes, J. Chambers, V. Shevchuk, G.E. Moore, F. Lammert, A.G. Glantz, L.A. Mattsson, J. Whittaker, M.G. Parker, R. White, and C. Williamson Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy Gastroenterology 133 2007 507 516
71. S. Fiorucci, C. Clerici, E. Antonelli, S. Orlandi, B. Goodwin, B.M. Sadeghpour, G. Sabatino, G. Russo, D. Castellani, T.M. Willson, M. Pruzanski, R. Pellicciari, and A. Morelli Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis J. Pharmacol. Exp. Ther. 313 2005 604 612
72. Y. Liu, J. Binz, M.J. Numerick, S. Dennis, G. Luo, B. Desai, K.I. MacKenzie, T.A. Mansfield, S.A. Kliewer, B. Goodwin, and S.A. Jones Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis J. Clin. Invest. 112 2003 1678 1687
73. S. Modica, M. Petruzzelli, E. Bellafante, S. Murzilli, L. Salvatore, N. Celli, T.G. Di, G. Palasciano, T. Moustafa, E. Halilbasic, M. Trauner, and A. Moschetta Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis Gastroenterology 142 2012 355 365
74. H.R. Kast, C.M. Nguyen, C.J. Sinal, S.A. Jones, B.A. Laffitte, K. Reue, F.J. Gonzalez, T.M. Willson, and P.A. Edwards Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids Mol. Endocrinol. 15 2001 1720 1728
75. T. Claudel, Y. Inoue, O. Barbier, D. Duran-Sandoval, V. Kosykh, J. Fruchart, J.C. Fruchart, F.J. Gonzalez, and B. Staels Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression Gastroenterology 125 2003 544 555
76. P.A. Mak, H.R. Kast-Woelbern, A.M. Anisfeld, and P.A. Edwards Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors J. Lipid Res. 43 2002 2037 2041
77. A. Sirvent, T. Claudel, G. Martin, J. Brozek, V. Kosykh, R. Darteil, D.W. Hum, J.C. Fruchart, and B. Staels The farnesoid X receptor induces very low density lipoprotein receptor gene expression FEBS Lett. 566 2004 173 177
78. A.M. Anisfeld, H.R. Kast-Woelbern, M.E. Meyer, S.A. Jones, Y. Zhang, K.J. Williams, T. Willson, and P.A. Edwards Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor J. Biol. Chem. 278 2003 20420 20428
79. Y. Zhang, L.W. Castellani, C.J. Sinal, F.J. Gonzalez, and P.A. Edwards Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR Genes Dev. 18 2004 157 169
80. M. Watanabe, S.M. Houten, L. Wang, A. Moschetta, D.J. Mangelsdorf, R.A. Heyman, D.D. Moore, and J. Auwerx Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c J. Clin. Invest. 113 2004 1408 1418
81. T. Pineda, I.T. Claudel, C. Duval, V. Kosykh, J.C. Fruchart, and B. Staels Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor Mol. Endocrinol. 17 2003 259 272
82. B. Cariou, H.K. van, D. Duran-Sandoval, T.H. van Dijk, A. Grefhorst, M. Abdelkarim, S. Caron, G. Torpier, J.C. Fruchart, F.J. Gonzalez, F. Kuipers, and B. Staels The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice J. Biol. Chem. 281 2006 11039 11049
83. H. Kurosu, M. Choi, Y. Ogawa, A.S. Dickson, R. Goetz, A.V. Eliseenkova, M. Mohammadi, K.P. Rosenblatt, S.A. Kliewer, and M. Kuro-o Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 J. Biol. Chem. 282 2007 26687 26695
84. M.J. Potthoff, J. Boney-Montoya, M. Choi, T. He, N.E. Sunny, S. Satapati, K. Suino-Powell, H.E. Xu, R.D. Gerard, B.N. Finck, S.C. Burgess, D.J. Mangelsdorf, and S.A. Kliewer FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway Cell Metab. 13 2011 729 738
85. H. Ge, H. Baribault, S. Vonderfecht, B. Lemon, J. Weiszmann, J. Gardner, K.J. Lee, J. Gupte, P. Mookherjee, M. Wang, J. Sheng, X. Wu, and Y. Li Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism PLoS One 7 2012 e33603
86. H.E. Bays, R.B. Goldberg, K.E. Truitt, and M.R. Jones Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects Arch. Intern. Med. 168 2008 1975 1983
87. T. Li, E. Owsley, M. Matozel, P. Hsu, C.M. Novak, and J.Y. Chiang Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice Hepatology 52 2010 678 690
88. Q. Shang, M. Saumoy, J.J. Holst, G. Salen, and G. Xu Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1 Am. J. Physiol. Gastrointest. Liver Physiol. 298 2010 G419 G424
89. M. Watanabe, Y. Horai, S.M. Houten, K. Morimoto, T. Sugizaki, E. Arita, C. Mataki, H. Sato, Y. Tanigawara, K. Schoonjans, H. Itoh, and J. Auwerx Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure J. Biol. Chem. 286 2011 26913 26920
90. V.A. Fonseca, J. Rosenstock, A.C. Wang, K.E. Truitt, and M.R. Jones Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy Diabetes Care 31 2008 1479 1484
91. A. Garg, and S.M. Grundy Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial Ann. Intern. Med. 121 1994 416 422
92. R.B. Goldberg, V.A. Fonseca, K.E. Truitt, and M.R. Jones Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy Arch. Intern. Med. 168 2008 1531 1540
93. R.S. Rosenson, S.L. Abby, and M.R. Jones Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes Atherosclerosis 204 2009 342 344
94. J. Rosenstock, V.A. Fonseca, W.T. Garvey, R.B. Goldberg, Y. Handelsman, S.L. Abby, Y.L. Lai, X. Jin, S. Misir, S. Nagendran, and M.R. Jones Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes Endocr. Pract. 16 2010 629 640
95. S.L. Schwartz, Y.L. Lai, J. Xu, S.L. Abby, S. Misir, M.R. Jones, and S. Nagendran The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study Metab. Syndr. Relat. Disord. 8 2010 179 188
96. B. Staels, and F. Kuipers Bile acid sequestrants and the treatment of type 2 diabetes mellitus Drugs 67 2007 1383 1392
97. F.J. Zieve, M.F. Kalin, S.L. Schwartz, M.R. Jones, and W.L. Bailey Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes Clin. Ther. 29 2007 74 83
98. F. Kuipers, V.W. Bloks, and A.K. Groen Beyond intestinal soap-bile acids in metabolic control Nat. Rev. Endocrinol. 10 2014 488 498
99. M. Watanabe, K. Morimoto, S.M. Houten, N. Kaneko-Iwasaki, T. Sugizaki, Y. Horai, C. Mataki, H. Sato, K. Murahashi, E. Arita, K. Schoonjans, T. Suzuki, H. Itoh, and J. Auwerx Bile acid binding resin improves metabolic control through the induction of energy expenditure PLoS One 7 2012 e38286
100. G. Brufau, A.K. Groen, and F. Kuipers Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion Arterioscler. Thromb. Vasc. Biol. 31 2011 1726 1733
101. J. Bruix, L. Boix, M. Sala, and J.M. Llovet Focus on hepatocellular carcinoma Cancer Cell 5 2004 215 219
102. Y. Deugnier, and B. Turlin Iron and hepatocellular carcinoma J. Gastroenterol. Hepatol. 16 2001 491 494
103. T. Propst, A. Propst, O. Dietze, G. Judmaier, H. Braunsteiner, and W. Vogel Alpha-1-antitrypsin deficiency and liver disease Dig. Dis. 12 1994 139 149
104. R. Cameron, K. Imaida, and N. Ito Promotive effects of deoxycholic acid on hepatocarcinogenesis initiated by diethylnitrosamine in male rats Gann 72 1981 635 636
105. I. Kim, K. Morimura, Y. Shah, Q. Yang, J.M. Ward, and F.J. Gonzalez Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice Carcinogenesis 28 2007 940 946
106. Y. Zhang, P. Xu, K. Park, Y. Choi, D.D. Moore, and L. Wang Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation Hepatology 48 2008 289 298
107. T. Chen, G. Xie, X. Wang, J. Fan, Y. Qiu, X. Zheng, X. Qi, Y. Cao, M. Su, X. Wang, L.X. Xu, Y. Yen, P. Liu, and W. Jia Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma Mol. Cell. Proteomics 10 2011 M110
108. A.S. Knisely, S.S. Strautnieks, Y. Meier, B. Stieger, J.A. Byrne, B.C. Portmann, L.N. Bull, L. Pawlikowska, B. Bilezikci, F. Ozcay, A. Laszlo, L. Tiszlavicz, L. Moore, J. Raftos, H. Arnell, B. Fischler, A. Nemeth, N. Papadogiannakis, J. Cielecka-Kuszyk, I. Jankowska, J. Pawlowska, H. Melin-Aldana, K.M. Emerick, P.F. Whitington, G. Mieli-Vergani, and R.J. Thompson Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency Hepatology 44 2006 478 486
109. M.J. Perez, and O. Briz Bile-acid-induced cell injury and protection World J. Gastroenterol. 15 2009 1677 1689
110. A. Wolfe, A. Thomas, G. Edwards, R. Jaseja, G.L. Guo, and U. Apte Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice J. Pharmacol. Exp. Ther. 338 2011 12 21
111. J.M. Ridlon, J.M. Alves, P.B. Hylemon, and J.S. Bajaj Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship Gut Microbes 4 2013 382 387
112. T. Inagaki, A. Moschetta, Y.K. Lee, L. Peng, G. Zhao, M. Downes, R.T. Yu, J.M. Shelton, J.A. Richardson, J.J. Repa, D.J. Mangelsdorf, and S.A. Kliewer Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor Proc. Natl. Acad. Sci. U. S. A. 103 2006 3920 3925
113. H. Li, X. Fu, Y. Chen, Y. Hong, Y. Tan, H. Cao, M. Wu, and H. Wang Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma Gastroenterology 128 2005 2029 2041
114. Y. Jiang, P. Iakova, J. Jin, E. Sullivan, V. Sharin, I.H. Hong, S. Anakk, A. Mayor, G. Darlington, M. Finegold, D. Moore, and N.A. Timchenko Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer Hepatology 57 2013 1098 1106
115. M. Nomoto, M. Miyata, S. Yin, Y. Kurata, M. Shimada, K. Yoshinari, F.J. Gonzalez, K. Suzuki, S. Shibasaki, T. Kurosawa, and Y. Yamazoe Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor Biol. Pharm. Bull. 32 2009 172 178
116. P. Fickert, A. Fuchsbichler, T. Moustafa, M. Wagner, G. Zollner, E. Halilbasic, U. Stoger, M. Arrese, M. Pizarro, N. Solis, G. Carrasco, A. Caligiuri, M. Sombetzki, E. Reisinger, O. Tsybrovskyy, K. Zatloukal, H. Denk, H. Jaeschke, M. Pinzani, and M. Trauner Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts Am. J. Pathol. 175 2009 2392 2405
117. N. He, K. Park, Y. Zhang, J. Huang, S. Lu, and L. Wang Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth Gastroenterology 134 2008 793 802
118. N. Liu, Z. Meng, G. Lou, W. Zhou, X. Wang, Y. Zhang, L. Zhang, X. Liu, Y. Yen, L. Lai, B.M. Forman, Z. Xu, R. Xu, and W. Huang Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression Mol. Endocrinol. 26 2012 775 785
119. H. Su, C. Ma, J. Liu, N. Li, M. Gao, A. Huang, X. Wang, W. Huang, and X. Huang Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma Am. J. Physiol. Gastrointest. Liver Physiol. 303 2012 G1245 G1253
120. D.C. Lee, Y.K. Kang, W.H. Kim, Y.J. Jang, D.J. Kim, I.Y. Park, B.H. Sohn, H.A. Sohn, H.G. Lee, J.S. Lim, J.W. Kim, E.Y. Song, D.M. Kim, M.N. Lee, G.T. Oh, S.J. Kim, K.C. Park, H.S. Yoo, J.Y. Choi, and Y.I. Yeom Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis Cancer Res. 68 2008 4210 4220
121. Y.J. Kim, S.Y. Yoon, J.T. Kim, E.Y. Song, H.G. Lee, H.J. Son, S.Y. Kim, D. Cho, I. Choi, J.H. Kim, and J.W. Kim NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma Carcinogenesis 30 2009 598 605
122. A. Lorentzen, L.K. Vogel, R.H. Lewinsky, M. Saebo, C.F. Skjelbred, S. Godiksen, G. Hoff, K.M. Tveit, I.M. Lothe, T. Ikdahl, E.H. Kure, and C. Mitchelmore Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma, BMC Cancer 7 2007 192
123. A. Piepoli, R. Cotugno, G. Merla, A. Gentile, B. Augello, M. Quitadamo, A. Merla, A. Panza, M. Carella, R. Maglietta, A. D'Addabbo, N. Ancona, S. Fusilli, F. Perri, and A. Andriulli Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour, BMC. Med Genomics 2 2009 11
124. H. Shi, N. Li, S. Li, C. Chen, W. Wang, C. Xu, J. Zhang, H. Jin, H. Zhang, H. Zhao, W. Song, Q. Feng, X. Feng, X. Shen, L. Yao, and Q. Zhao Expression of NDRG2 in esophageal squamous cell carcinoma Cancer Sci. 101 2010 1292 1299
125. S.P. Song, S.B. Zhang, R. Liu, L. Yao, Y.Q. Hao, M.M. Liao, Y.D. Zhang, and Z.H. Li NDRG2 down-regulation and CD24 up-regulation promote tumor aggravation and poor survival in patients with gallbladder carcinoma Med. Oncol. 29 2012 1879 1885
126. M. Tepel, P. Roerig, M. Wolter, D.H. Gutmann, A. Perry, G. Reifenberger, and M.J. Riemenschneider Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma Int. J. Cancer 123 2008 2080 2086
127. U. Deuschle, J. Schuler, A. Schulz, T. Schluter, O. Kinzel, U. Abel, and C. Kremoser FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model PLoS. One. 7 2012 e43044
128. C. Degirolamo, S. Modica, M. Vacca, T.G. Di, A. Morgano, A. D'Orazio, K. Kannisto, P. Parini, and A. Moschetta Prevention of spontaneous hepatocarcinogenesis in FXR null mice by intestinal specific FXR re-activation Hepatology 2014 (Epub ahead of print)
129. R.R. Maran, A. Thomas, M. Roth, Z. Sheng, N. Esterly, D. Pinson, X. Gao, Y. Zhang, V. Ganapathy, F.J. Gonzalez, and G.L. Guo Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development J. Pharmacol. Exp. Ther. 328 2009 469 477
130. S. Modica, S. Murzilli, L. Salvatore, D.R. Schmidt, and A. Moschetta Nuclear bile acid receptor FXR protects against intestinal tumorigenesis Cancer Res. 68 2008 9589 9594
131. L.V. Karsa, T.A. Lignini, J. Patnick, R. Lambert, and C. Sauvaget The dimensions of the CRC problem Best Pract. Res. Clin. Gastroenterol. 24 2010 381 396
132. M.L. Slattery Diet, lifestyle, and colon cancer Semin. Gastrointest. Dis. 11 2000 142 146
133. M. Peterlik Role of bile acid secretion in human colorectal cancer Wien. Med. Wochenschr. 158 2008 539 541
134. F. Bianchini, G. Caderni, P. Dolara, L. Fantetti, and D. Kriebel Effect of dietary fat, starch and cellulose on fecal bile acids in mice J. Nutr. 119 1989 1617 1624
135. B.S. Reddy, A.R. Hedges, K. Laakso, and E.L. Wynder Metabolic epidemiology of large bowel cancer: fecal bulk and constituents of high-risk North American and low-risk Finnish population Cancer 42 1978 2832 2838
136. E. Giovannucci, G.A. Colditz, and M.J. Stampfer A meta-analysis of cholecystectomy and risk of colorectal cancer Gastroenterology 105 1993 130 141
137. J. Lagergren, W. Ye, and A. Ekbom Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? Gastroenterology 121 2001 542 547
138. P.R. Debruyne, E.A. Bruyneel, X. Li, A. Zimber, C. Gespach, and M.M. Mareel The role of bile acids in carcinogenesis Mutat. Res. 480-481 2001 359 369
139. P.R. Debruyne, E.A. Bruyneel, I.M. Karaguni, X. Li, G. Flatau, O. Muller, A. Zimber, C. Gespach, and M.M. Mareel Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways Oncogene 21 2002 6740 6750
140. A. Zimber, A. Chedeville, C. Gespach, and J.P. Abita Inhibition of proliferation and induction of monocytic differentiation on HL60 human promyelocytic leukemia cells treated with bile acids in vitro Int. J. Cancer 59 1994 71 77
141. A. Zimber, A. Chedeville, J.P. Abita, V. Barbu, and C. Gespach Functional interactions between bile acids, all-trans retinoic acid, and 1,25-dihydroxy-vitamin D3 on monocytic differentiation and myeloblastin gene down-regulation in HL60 and THP-1 human leukemia cells Cancer Res. 60 2000 672 678
142. A. Zimber, and C. Gespach Bile acids and derivatives, their nuclear receptors FXR, PXR and ligands: role in health and disease and their therapeutic potential Anticancer. Agents Med. Chem. 8 2008 540 563
143. T.A. Ullman, and S.H. Itzkowitz Intestinal inflammation and cancer Gastroenterology 140 2011 1807 1816
144. M.J. Hill, D.M. Melville, J.E. Lennard-Jones, K. Neale, and J.K. Ritchie Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis Lancet 2 1987 185 186
145. J. Torres, X. Bao, A.C. Iuga, A. Chen, N. Harpaz, T. Ullman, B.L. Cohen, C.G. Pineton de, S. Asciutti, J.A. Odin, D.B. Sachar, H.R. Gaskins, K. Setchell, J.F. Colombel, and S.H. Itzkowitz Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia Inflamm. Bowel Dis. 19 2013 275 282
146. S. Lax, G. Schauer, K. Prein, M. Kapitan, D. Silbert, A. Berghold, A. Berger, and M. Trauner Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis Int. J. Cancer 130 2012 2232 2239
147. G.A. De, F. Touri, C.A. Maurer, A. Perez, O. Maurhofer, G. Ventre, C.L. Bentzen, E.J. Niesor, and J.F. Dufour The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer Dig. Dis. Sci. 49 2004 982 989
148. A.M. Bailey, L. Zhan, D. Maru, I. Shureiqi, C.R. Pickering, G. Kiriakova, J. Izzo, N. He, C. Wei, V. Baladandayuthapani, H. Liang, S. Kopetz, G. Powis, and G.L. Guo FXR silencing in human colon cancer by DNA methylation and KRAS signaling Am. J. Physiol. Gastrointest. Liver Physiol. 306 2014 G48 G58
149. K. Oguma, H. Oshima, M. Aoki, R. Uchio, K. Naka, S. Nakamura, A. Hirao, H. Saya, M.M. Taketo, and M. Oshima Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells EMBO J. 27 2008 1671 1681
150. D.L. Smith, P. Keshavan, U. Avissar, K. Ahmed, and S.D. Zucker Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor Carcinogenesis 31 2010 1100 1109
151. Z. Peng, J.P. Raufman, and G. Xie Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis PLoS One 7 2012 e48461
152. S.I. Sayin, A. Wahlstrom, J. Felin, S. Jantti, H.U. Marschall, K. Bamberg, B. Angelin, T. Hyotylainen, M. Oresic, and F. Backhed Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist Cell Metab. 17 2013 225 235
153. V. Tremaroli, and F. Backhed Functional interactions between the gut microbiota and host metabolism Nature 489 2012 242 249